Michael Okunewitch
Stock Analyst at Maxim Group
(0.23)
# 4,226
Out of 4,407 analysts
371
Total ratings
36%
Success rate
-4.9%
Average return
Main Sectors:
Stocks Rated by Michael Okunewitch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CTOR Citius Oncology | Maintained: Buy | $4 | $0.664 | +502.41% | 12 | Jun 2, 2026 | |
| MDWD MediWound | Maintained: Buy | $30 | $14.22 | +110.97% | 27 | Jun 1, 2026 | |
| HCWB HCW Biologics | Rated: Buy | $2 → $5 | $1.28 | +290.63% | 23 | May 29, 2026 | |
| BLTE Belite Bio | Maintained: Buy | $200 | $138.16 | +44.76% | 13 | May 27, 2026 | |
| RANI Rani Therapeutics Holdings | Maintained: Buy | $5 | $0.7601 | +557.81% | 14 | May 21, 2026 | |
| AIDX 20/20 Biolabs | Maintained: Buy | $5 | - | - | 2 | May 21, 2026 | |
| GILD Gilead Sciences | Upgraded: Buy | $165 | $125.59 | +31.38% | 23 | May 20, 2026 | |
| CMMB Chemomab Therapeutics | Maintained: Buy | $5 | $1.65 | +203.03% | 12 | May 18, 2026 | |
| ACRV Acrivon Therapeutics | Rated: Buy | $7 | $1.48 | +372.97% | 12 | May 18, 2026 | |
| LCTX Lineage Cell Therapeutics | Maintained: Buy | $3 | $1.27 | +136.22% | 15 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $40 | $24.75 | +61.62% | 14 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.7826 | - | 24 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $2.55 | +370.59% | 29 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $3.64 | +174.73% | 3 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 | $1.21 | +561.16% | 22 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.931 | - | 8 | May 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $10 → $12 | $1.92 | +525.00% | 2 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $1 | $0.3525 | +183.69% | 23 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $12.08 | -0.66% | 10 | Mar 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 | $4.27 | +251.29% | 7 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $10 | $3.92 | +155.10% | 19 | Mar 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.73 | - | 6 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.38 | - | 1 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $0.54 | - | 28 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $6.9 | $1.21 | +470.25% | 6 | Sep 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $4.21 | n/a | 1 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $0.6145 | n/a | 11 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $0.60 | n/a | 4 | May 9, 2023 |
Citius Oncology
Jun 2, 2026
Maintained: Buy
Price Target: $4
Current: $0.664
Upside: +502.41%
MediWound
Jun 1, 2026
Maintained: Buy
Price Target: $30
Current: $14.22
Upside: +110.97%
HCW Biologics
May 29, 2026
Rated: Buy
Price Target: $2 → $5
Current: $1.28
Upside: +290.63%
Belite Bio
May 27, 2026
Maintained: Buy
Price Target: $200
Current: $138.16
Upside: +44.76%
Rani Therapeutics Holdings
May 21, 2026
Maintained: Buy
Price Target: $5
Current: $0.7601
Upside: +557.81%
20/20 Biolabs
May 21, 2026
Maintained: Buy
Price Target: $5
Current: -
Upside: -
Gilead Sciences
May 20, 2026
Upgraded: Buy
Price Target: $165
Current: $125.59
Upside: +31.38%
Chemomab Therapeutics
May 18, 2026
Maintained: Buy
Price Target: $5
Current: $1.65
Upside: +203.03%
Acrivon Therapeutics
May 18, 2026
Rated: Buy
Price Target: $7
Current: $1.48
Upside: +372.97%
Lineage Cell Therapeutics
May 14, 2026
Maintained: Buy
Price Target: $3
Current: $1.27
Upside: +136.22%
May 11, 2026
Maintained: Buy
Price Target: $40
Current: $24.75
Upside: +61.62%
May 11, 2026
Downgraded: Hold
Price Target: n/a
Current: $0.7826
Upside: -
May 8, 2026
Maintained: Buy
Price Target: $12
Current: $2.55
Upside: +370.59%
May 7, 2026
Maintained: Buy
Price Target: $10
Current: $3.64
Upside: +174.73%
May 6, 2026
Maintained: Buy
Price Target: $8
Current: $1.21
Upside: +561.16%
May 4, 2026
Downgraded: Hold
Price Target: n/a
Current: $0.931
Upside: -
Apr 9, 2026
Rated: Buy
Price Target: $10 → $12
Current: $1.92
Upside: +525.00%
Apr 8, 2026
Maintained: Buy
Price Target: $1
Current: $0.3525
Upside: +183.69%
Mar 26, 2026
Maintained: Buy
Price Target: $12
Current: $12.08
Upside: -0.66%
Mar 25, 2026
Maintained: Buy
Price Target: $15
Current: $4.27
Upside: +251.29%
Mar 17, 2026
Rated: Buy
Price Target: $10
Current: $3.92
Upside: +155.10%
Mar 6, 2026
Downgraded: Hold
Price Target: n/a
Current: $1.73
Upside: -
Dec 3, 2025
Downgraded: Hold
Price Target: n/a
Current: $1.38
Upside: -
Sep 23, 2025
Maintained: Hold
Price Target: n/a
Current: $0.54
Upside: -
Sep 13, 2025
Maintained: Hold
Price Target: $6.9
Current: $1.21
Upside: +470.25%
Mar 3, 2025
Maintained: Buy
Price Target: $12
Current: $4.21
Upside: n/a
Sep 13, 2024
Maintained: Buy
Price Target: $12
Current: $0.6145
Upside: n/a
May 9, 2023
Maintained: Buy
Price Target: n/a
Current: $0.60
Upside: n/a